Boston Scientific: Analysts Cheer Growth, Raise Targets

Boston Scientific's financial trajectory continues to draw analyst attention, with fair value targets holding firm and numerous price target increases reported. This sustained confidence stems from the company's recent strong performance, particularly its third-quarter results and accelerated growth from the Watchman device. Analysts are increasingly optimistic about Boston Scientific's ability to surpass guidance.

Several major financial institutions have revised their outlooks upward. Truist, Morgan Stanley, and Barclays, among others, have raised their price targets, citing improvements in organic growth, earnings per share projections, and a favorable business mix. The Nalu Medical acquisition has also been noted as a strategic move aligning with the company's history of value creation through early-stage investments and M&A.